A real-world analysis of nearly 5,000 men with metastatic hormone-sensitive prostate cancer points to a PSA threshold that may better predict outcomes than the typical percentage decline. The study suggests that patients whose PSA drops below 0.2 ng/mL within nine months of starting therapy face substantially different survival outcomes. By focusing on an absolute biomarker milestone—rather than the magnitude of PSA reduction—the work aims to refine how clinicians interpret biochemical response in routine practice. The analysis strengthens the case for using PSA kinetics in standardized ways across care settings. Clinically, the findings could influence monitoring rules for treatment continuation, escalation decisions, and risk stratification for men undergoing hormone-based regimens.